Immunovant Inc. (IMVT) Financial Statements (2024 and earlier)

Company Profile

Business Address 320 WEST 37TH STREET
NEW YORK, NY 10018
State of Incorp. DE
Fiscal Year End March 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments690,937,000269,928,000329,960,000376,532,000432,608,000405,773,000
Cash and cash equivalents690,937,000269,928,000329,960,000376,532,000432,608,000405,773,000
Receivables1,029,0001,421,000823,000885,000704,0003,782,000
Prepaid expense18,810,00019,828,00019,232,00026,916,00021,110,00016,536,000
Total current assets:710,776,000291,177,000350,015,000404,333,000454,422,000426,091,000
Noncurrent Assets
Operating lease, right-of-use asset294,000589,000882,0001,172,0001,459,0001,743,000
Property, plant and equipment376,000304,000325,000333,000362,000312,000
Total noncurrent assets:670,000893,0001,207,0001,505,0001,821,0002,055,000
TOTAL ASSETS:711,446,000292,070,000351,222,000405,838,000456,243,000428,146,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,796,00039,645,00050,438,00041,774,00040,054,00034,206,000
Employee-related liabilities3,607,000
Accounts payable3,910,0007,511,00026,459,0001,353,00014,004,0007,461,000
Accrued liabilities27,886,00032,134,00023,979,00040,421,00026,050,00023,138,000
Other liabilities      
Due to related parties350,000  
Other undisclosed current liabilities306,000614,000919,0001,173,0001,205,000(2,422,000)
Total current liabilities:32,102,00040,259,00051,357,00043,297,00041,259,00031,784,000
Noncurrent Liabilities
Long-term debt and lease obligation:      614,000
Liabilities, other than long-term debt    47,000306,000 
Operating lease, liability    47,000306,000614,000
Other undisclosed noncurrent liabilities      (614,000)
Total noncurrent liabilities:    47,000306,000614,000
Total liabilities:32,102,00040,259,00051,357,00043,344,00041,565,00032,398,000
Equity
Equity, attributable to parent679,344,000251,811,000299,865,000362,494,000414,678,000395,748,000
Common stock14,00013,00013,00013,00013,00012,000
Additional paid in capital1,430,294,000950,231,000939,554,000927,976,000920,197,000840,661,000
Accumulated other comprehensive income (loss)(600,000)513,000582,000852,0001,383,000(1,237,000)
Accumulated deficit(750,364,000)(698,946,000)(640,284,000)(566,347,000)(506,915,000)(443,688,000)
Total equity:679,344,000251,811,000299,865,000362,494,000414,678,000395,748,000
TOTAL LIABILITIES AND EQUITY:711,446,000292,070,000351,222,000405,838,000456,243,000428,146,000

Income Statement (P&L) (USD)

3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
Operating expenses(61,553,000)(61,800,000)(78,477,000)(109,470,000)(64,027,000)(49,614,000)
Operating loss:(61,553,000)(61,800,000)(78,477,000)(109,470,000)(64,027,000)(49,614,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
1,094,00020,000464,000572,000(1,757,000)793,000
Loss from continuing operations before equity method investments, income taxes:(60,459,000)(61,780,000)(78,013,000)(108,898,000)(65,784,000)(48,821,000)
Other undisclosed income from continuing operations before income taxes8,933,0003,572,0004,065,0007,578,0002,944,0001,154,000
Loss from continuing operations before income taxes:(51,526,000)(58,208,000)(73,948,000)(101,320,000)(62,840,000)(47,667,000)
Income tax expense (benefit)108,000(454,000)11,000(81,000)(387,000)(261,000)
Loss from continuing operations:(51,418,000)(58,662,000)(73,937,000)(101,401,000)(63,227,000)(47,928,000)
Loss before gain (loss) on sale of properties:(47,928,000)
Net loss available to common stockholders, diluted:(51,418,000)(58,662,000)(73,937,000)(101,401,000)(63,227,000)(47,928,000)

Comprehensive Income (USD)

3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
Net loss:(51,418,000)(58,662,000)(73,937,000)(101,401,000)(63,227,000)(47,928,000)
Other comprehensive income (loss)(1,113,000)69,000270,000(269,000)2,620,000(974,000)
Comprehensive loss, net of tax, attributable to parent:(52,531,000)(58,593,000)(73,667,000)(101,670,000)(60,607,000)(48,902,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: